Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

European Journal of Surgical Oncology

Volumn 40, Issue 10, 2014, Pages 1165-1176

  Glynne Jones, R ^a   Nilsson, P J ^b   Aschele, C ^c   Goh, V ^d   Peiffert, D ^e   Cervantes, A ^f   Arnold, D ^g  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Felettino Hospital   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e CENTRE ALEXIS VAUTRIN   (France)

^f UNIVERSITY OF VALENCIA   (Spain)

^g TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Anal cancer; Diagnosis; Follow up; Guidelines; Treatment

Indexed keywords

FLUOROURACIL; MITOMYCIN;

ANUS CARCINOMA; ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; FOLLOW UP; HUMAN; LYMPHATIC DRAINAGE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRESERVATION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT RESPONSE; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; FEMALE; LYMPH NODE METASTASIS; MALE; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PROGNOSIS; STANDARDS; VIROLOGY;

ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MEDICAL ONCOLOGY; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 84920936576     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.07.030     Document Type: Review

References (25)

1. A. Jemal, E.P. Simard, and C. Dorell et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels J Natl Cancer Inst 105 2013 175 201
2. J.M. Palefsky, A.R. Giuliano, and S. Goldstone et al. HPV vaccine against anal HPV infection and Anal Intraepithelial Neoplasia N Engl J Med 365 2011 1576 1585
3. V. Goh, F.K. Gollub, and J. Liaw et al. Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys 78 2010 715 721
4. H. Bartelink, F. Roelofsen, and F. Eschwege et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups J Clin Oncol 15 1997 2040 2049
5. British HIV Association British Association of sexual health and HIV 2008 British Infection Society UK National Guidelines for HIV Testing www.bhiva.org/hivtesting2008.aspx [accessed 14.04. 14]
6. C. Oehler-Jänne, F. Huguet, and S. Provencher et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy J Clin Oncol 26 2008 2550 2557
7. A. Wexler, A.M. Berson, and S.E. Goldstone et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy Dis Colon Rectum 51 2008 73 81
8. I. Fraunholz, D. Rabeneck, and J. Gerstein et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 98 2011 99 104
9. UKCCCR Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research Lancet 348 1996 1049 1054
10. M. Flam, M. John, and T.F. Pajak et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study J Clin Oncol 14 1996 2527 2539
11. J.A. Ajani, K.A. Winter, and L.L. Gunderson et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial JAMA 299 2008 1914 1921
12. D. Peiffert, L. Tournier-Rangeard, and J.P. Gérard et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial J Clin Oncol 30 2012 1941 1948
13. R.D. James, R. Glynne-Jones, and H.M. Meadows et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial Lancet Oncol 14 2013 516 524
14. L.L. Gunderson, K.A. Winter, and J.A. Ajani et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin J Clin Oncol 30 2012 4344 4351
15. N.D. Nigro, V.K. Vaitkevicius, and B. Considine Jr. Combined therapy for cancer of the anal canal: a preliminary report Dis Colon Rectum 17 1974 354 356
16. B.J. Cummings, T.J. Keane, and B. O'Sullivan et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C Int J Radiat Oncol Biol Phys 21 1991 1115 1125
17. L.A. Kachnic, H.K. Tsai, and J.J. Coen et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy Int J Radiat Oncol Biol Phys 82 2012 153 158
18. L.A. Kachnic, K. Winter, and R.J. Myerson et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal Int J Radiat Oncol Biol Phys 86 2013 27 33
19. M. Ng, T. Leong, and S. Chander et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer Int J Radiat Oncol Biol Phys 83 2012 1455 1462
20. R.J. Myerson, M.C. Garofalo, and I. El Naqa et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas Int J Radiat Oncol Biol Phys 74 2009 824 830
21. R. Glynne-Jones, R. James, and H. Meadows et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. 2012 ASCO Annual Meeting (abstr 4004) J Clin Oncol 30 Suppl. 2012 abstr 4004
22. T. Lampejo, D. Kavanagh, and J. Clark et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review Br J Cancer 103 2010 1858 1869
23. A.G. Bentzen, L. Balteskard, and E.H. Wanderås et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors Acta Oncol 52 2013 736 744
24. A.G. Bentzen, M.G. Guren, and B. Vonen et al. Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort Radiother Oncol 108 2013 55 60
25. K.G. Sunesen, S. Buntzen, and T. Tei et al. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap Ann Surg Oncol 16 2009 68 77